Clinicopathological Features and Oncological Outcomes of Early and Late Recurrence in Stage III Colorectal Cancer Patients after Adjuvant Oxaliplatin-Based Therapy

Table 1

Clinicopathological features of 128 stage III CRC patients developed recurrence after adjuvant oxaliplatin-based regimen.

Characteristics	N	(%)
Gender
Female	49	(38.3)
Male	79	(61.7)
Age (years)
≤57	41	(32.0)
>57	87	(68.0)
Tumor size (cm)
≥5	47	(36.7)
<5	81	(63.3)
Tumor location
Right-sided colon	42	(32.8)
Left-sided colon	86	(67.2)
Pathological staging
Depth of tumor invasion
T1 + T2 + T3	102	(79.7)
T4	26	(20.3)
Lymph node metastasis
N1	68	(53.1)
N2	60	(46.9)
Histopathology grade
Well differentiated	0	(0)
Moderately differentiated	110	(85.9)
Poorly differentiated	18	(14.1)
Lymph-vascular invasion
No	43	(33.6)
Yes	85	(66.4)
Perineural invasion
No	56	(43.7)
Yes	72	(56.3)
Preoperative serum CEA level (ng/ml)
<5	75	(58.6)
≥5	53	(41.4)
Postoperative serum CEA level (ng/ml)
<5	107	(83.6)
≥5	21	(16.4)
Cycles of oxaliplatin-based regimen (cycles)
≤8	40	(31.2)
>8	88	(68.8)
Pattern of recurrence/distant metastasis
Local recurrence	49	(38.3)
Distal metastasis	79	(61.7)
Recurrence from first cycle of mFOLFOX
Early recurrence	47	(36.7)
Late recurrence	81	(63.3)

CEA: carcinoembryonic antigen.